Yahoo
HKSE - Delayed Quote HKD

InnoCare Pharma Limited (9969.HK)

15.370 +0.600 (+4.06%)
At close: September 4 at 4:08:02 PM GMT+8
Chart Range Bar
Loading chart for 9969.HK
  • Previous Close 14.770
  • Open 14.830
  • Bid 15.360 x --
  • Ask 15.370 x --
  • Day's Range 14.830 - 15.600
  • 52 Week Range 9.650 - 20.180
  • Volume 14,484,000
  • Avg. Volume 8,933,211
  • Market Cap (intraday) 27.153B
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 24.40
  • EPS (TTM) 0.630
  • Earnings Date Aug 24, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 20.26

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

www.innocarepharma.com

1,388

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

9969.HK
25.26%
HANG SENG INDEX (^HSI)
0.08%

1-Year Return

9969.HK
11.82%
HANG SENG INDEX (^HSI)
2.36%

3-Year Return

9969.HK
126.70%
HANG SENG INDEX (^HSI)
36.12%

5-Year Return

9969.HK
31.08%
HANG SENG INDEX (^HSI)
0.97%

Analyst Insights

View More

Analyst Price Targets

17.18
20.26 Average
15.370 Current
22.74 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    33.05%

  • Return on Assets (ttm)

    4.28%

  • Return on Equity (ttm)

    12.77%

  • Revenue (ttm)

    2.78B

  • Net Income Avi to Common (ttm)

    918.91M

  • Diluted EPS (ttm)

    0.630

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.89B

  • Total Debt/Equity (mrq)

    29.05%

  • Levered Free Cash Flow (ttm)

    104.44M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: